Compare Roivant Sciences Ltd. Common Shares (ROIV) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roivant Sciences Ltd. Common Shares vs Synopsys, Inc. — how do they compare? Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B), while Synopsys, Inc. trades at $502 (market cap $96.33B). The key difference: Synopsys, Inc. is far larger — about 3.8× Roivant Sciences Ltd. Common Shares's market cap, and Roivant Sciences Ltd. Common Shares is more actively traded (5,738,571 versus 1,631,837). Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 0 Days and Synopsys, Inc. for 71 Days on average.
| ROIV | SNPS | |
|---|---|---|
Market Cap | $25.09B | $96.33B |
Volume | 5,738,571 | 1,631,837 |
Sector | Health | Technology |
52-Week High | $41.81 | $534.56 |
52-Week Low | $16.04 | $367.70 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $21.36B | $103.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synopsys (SNPS) trades at $497.75, down 1.47% on the day but remains near recent highs following strong quarterly earnings beats and bullish investor sentiment driven by AI partnerships. The stock shows a bullish technical trend with moving averages supporting upside, while RSI levels indicate overbought conditions. Recent news highlights multi-year agreements with OpenAI and Amazon Web Services, fueling growth expectations beyond traditional EDA markets.
The outlook is positive with a consensus price target of $572.54, reflecting 15% upside potential, though high valuation multiples (P/E of 87.73) and integration risks from the Ansys acquisition warrant caution. Revenue growth is projected to accelerate, supported by AI-driven demand, but margin compression and competitive pressures pose medium-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
